



NEWS RELEASE

ANTARES PHARMA TO PRESENT AT THE JMP SECURITIES LIFE SCIENCES CONFERENCE

EWING, NJ, June 16, 2015 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Tuesday, June 23, 2015 at 1:30 p.m. Eastern Time.

A live webcast of the presentation will be available via the webcast tab under the Investor Information page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares' website for 90 days following the presentation.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company's product, OTREXUP™ (methotrexate) injection for subcutaneous use, is approved in the U.S. for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot® Testosterone for testosterone replacement therapy, and VIBEX® Sumatriptan for the acute treatment of migraines. The Company's technology platforms include VIBEX® disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd. that includes VIBEX® epinephrine, exenatide multi-dose pen, and another undisclosed multi-dose pen. Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring B.V.

Contact:

Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com